Tel Aviv and Oslo – September 15, 2026 -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) and Hemispherian AS will present two abstracts on their oncology candidate GLIX1 at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) in Rome, Italy, September 24-27, with one abstract selected for oral presentation.

Burlington, N.C. – September 15, 2026 -- Labcorp (NYSE: LH) reaffirmed its full-year 2026 guidance and unveiled a long-term outlook through 2029 projecting compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share growth of 8.5% to 11.5%, the company said at its 2026 Investor Day.

Basel – September 15, 2026 -- CordenPharma is committing €80 million in multi-year capital expenditure to expand aseptic fill-finish capacity at its FDA- and EMA-approved Caponago site near Milan, targeting total production capacity of up to 500 million sterile injectable units annually.

Delft, Netherlands – September 15, 2026 -- AdJane Biosciences has published a technical white paper detailing a strategy to add a proprietary mucosal-immunity booster to established intramuscular respiratory vaccine franchises, using its clinically validated Nm-nOMV platform derived from Neisseria meningitidis outer membrane vesicles.

Delft – September 15, 2026 -- AdJane Biosciences has published a White Paper outlining a strategy to add a proprietary intranasal booster to existing intramuscular respiratory vaccines, targeting the mucosal immunity gap left by current mRNA shots.

Delft – September 15, 2026 -- AdJane Biosciences has published a white paper outlining a strategy to add mucosal immune stimulation to existing intramuscular respiratory vaccine regimens, using its clinically validated Nm-nOMV platform derived from Neisseria meningitidis outer membrane vesicles.

Basel, Switzerland – September 15, 2026 -- CordenPharma has committed a multi-year €80 million investment to expand sterile injectable manufacturing at its FDA & EMA-approved Caponago site near Milan, Italy, targeting a total production capacity of 500 million units per year.

Basel – September 15, 2026 -- CordenPharma has committed a multi-year €80 million investment to expand sterile injectable manufacturing at its Caponago, Italy site, targeting total production capacity of up to 500 million injectable units per year.

Cambridge – – September 15, 2026 -- Insilico Medicine (HKEX: 3696) has dosed the first patient in GENESIS-IPF-3, a Phase III trial of Rentosertib, marking what the company calls the world's first late-stage clinical study of a drug candidate discovered and developed using generative AI.

Durham – September 15, 2026 -- Seismic Pharmaceuticals has enrolled the first patient in RESCUE HF-CS, a global Phase 3 trial testing istaroxime as a potential first-ever approved drug for heart-failure-related cardiogenic shock, a condition with no FDA-approved treatment.

Trial to enroll 600 patients across four continents

The study will recruit approximately 600 patients at clinical sites in the United States, Europe, China and South America. It builds on four completed Phase 2 trials that enrolled more than 350 patients.